AloCELYVIR
Biologic
AloCELYVIR is one of 87 biologic programs targeting Diffuse Intrinsic Pontine Glioma. It is currently in development.
2
Indications
2
Total Trials
1
Active Trials
86
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
90 competitors in Uveal Melanoma
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerPhase 3
Koselugo
AstraZenecaPhase 3
Yervoy
Bristol-Myers SquibbPhase 2
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
KIMMTRAK
IImmunocore Ltd
Phase 3
Keytruda
Merck & Co.Phase 2
Mekinist
NovartisPhase 2
Nexavar
BayerPhase 2
Sutent
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diffuse Intrinsic Pontine Glioma1 trial
Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
Active, not recruiting·HHospital Infantil Universitario Niño Jesús, Madrid, Spain·Phase 1/2·NCT04758533·13 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AloCELYVIR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]